American Society of Pain and Neuroscience ASPN

Numerous studies conducted by Dana-Farber researchers show promising results for patients with endometrial, lung, breast, prostate, and colorectal cancers. The results of these studies, along with dozens of others led by Dana-Farber faculty, were presented at this year’s American Association for Cancer Research (AACR) Annual Meeting last month in California.   Notable research from Dana-Farber researchers included: Novel ADC and Immunotherapy Combo Shows Promise in Endometrial Cancer Subtype  Rebecca Porter, MD, PhD, a medical oncologist in the Gynecological Oncology Program of the Susan F. Smith Center for Women’s Cancers, presented results of a small, investigator-initiated phase 2 study of a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor. Blood Test May Identify Patients with Non-Small Cell Lung Cancer Subtype Who Can Benefit from Combination Therapy  Pasi Jänne, MD, PhD, senior vice president for Translational Medicine, presented an update to his practice-changing FLAURA2 clinical trial published last year, revealing that patients with non-small cell lung cancer (NSCLC) marked by a mutation in the EGFR gene fared significantly better when treated with the drug osimertinib plus platinum-based chemotherapy than with osimertinib alone. Exercise Program Can Improve Heart Function in Cancer Survivors  Cami Christopher, MPH, a research scientist in the Department of Medical Oncology, Population Sciences, presented findings suggesting that a moderate to vigorous aerobic and resistance exercise program can improve a key aspect of heart function in survivors of breast, prostate, and colorectal cancer. Study Provides First Large-Scale Look at Genetic Architecture of Prostate Cancer in Sub-Saharan Africa  Timothy Rebbeck, PhD, the Vincent L. Gregory Professor of Cancer Prevention, led the first large-scale genomic analysis of prostate cancer in sub-Saharan Africa which revealed that the genetic architecture of the disease – its basic underpinnings in abnormalities in DNA – is unique to Africa and varies across the continent. In addition, the AACR recognized Rebbeck, Christopher D.M. Fletcher, MD, FRCPath, and Gordon J. Freeman, PhD, with 2024 Scientific Achievement Awards during the Annual Meeting.  More: https://lnkd.in/etk8fwUp

58

1 Comment

The mental health world is on edge as we await the FDA's verdict on MDMA-assisted therapy for PTSD. But what's really at stake? In our latest Psychiatry Tomorrow podcast, Carlene MacMillan, MD, FCTMSS, DFAACAP sat down with experts Owen Muir MD DFAACAP, Boris Heifets, M.D, PhD, and Andrew Penn, RN, NP, CNS, PMHNP-BC to unpack this pivotal moment in psychiatry. We dove deep into: -The tug-of-war between clinical enthusiasm and regulatory caution ( clinician survey results) -How to think about "functional unblinding" in MDMA and psychedelic trials -Safety and long-term outcomes to safeguard MDMA -Who's qualified to guide these transformative experiences? -What does the future hold for other psychedelic treatments? Plus, we tackled the million-dollar question: Will the FDA give the green light?🚦 Whether you're a mental health clinician, researcher, or just curious about the future of PTSD treatment, this episode is a must-listen. Tune in or read the summary of the discussion below. Or, search “Psychiatry Tomorrow” on your favorite podcast player. What are your thoughts on MDMA-assisted therapy and the FDA’s decision? Share below! 👇 https://lnkd.in/drJyK2xh

12